Neurologix has announced efficacy results from the Phase II clinical trial of gene therapy agent NLX-P101, used for the treatment of Parkinson’s disease.

The trial included 45 subjects with moderate to advanced Parkinson’s disease and demonstrated that treatment with NLX-P101 improved the primary motor symptoms of Parkinson’s disease in patients.

Neurologix scientific co-founder Matthew J During said the results demonstrated that treatment with gene therapy agent showed the clinically meaningful improvement and durability over the long-term.

Parkinson’s disease is a progressive and debilitating neurodegenerative disorder that affects the control of bodily movement.

NLX-P101 modulates the activity of the STN, which is overactive in patients with Parkinson’s disease, by restoring GABA, a neurotransmitter important in STN function.